BioLineRx joins Merck’s clique of immuno-oncology partners

Damian Garde Israeli drug developer BioLineRx is partnering with Merck to see whether its in-development cancer therapy can work in tandem with an approved treatment that taps the power ...

Pharma scandals spawn investor lawsuits at KaloBios, Sequoia

Carly Helfand Angry investors of KaloBios and Sequoia Fund are taking their pharma grievances to the courts. FiercePharma News

If hospitalized Valeant chief makes an exit, it’ll be without a golden parachute

Carly Helfand On Wednesday, Valeant put former CFO Howard Schiller into the CEO's position to replace hospitalized chief J. Michael Pearson on an interim basis. But if Pearson doesn't ...

Juno buys into sequencing; Moderna cozies up to Big Pharma; and more from #JPM16

Damian Garde In the requisite flood of dealmaking that marks day one of San Francisco's annual J.P. Morgan Healthcare Conference, high-profile biotechs Juno Therapeutics and Moderna ...

Vertex’s 2016 outlook falls short amid mixed results from high-profile CF meds

Carly Helfand SAN FRANCISCO–Cystic fibrosis specialist Vertex announced 2015 Kalydeco sales that topped analyst expectations, in advance of a presentation at the ...

Another Chinese biopharma lines up for a billion-dollar IPO

Damian Garde Chinese drugmaker Simcere Pharmaceutical is plotting a Hong Kong IPO worth up to $ 1 billion, according to reports, joining a slew of local biopharma companies headed ...

GSK’s new $32,500 asthma med costs at least 2X too much, U.S. pricing watchdog says

Carly Helfand GlaxoSmithKline has a new drug that's tailored for patients with a specific type of severe asthma. But according to a nonprofit body that evaluates drugs' prices ...

Doctors target Catalyst Pharma’s forthcoming pricing on old-turned-new med Firdapse

Tracy Staton A new group of activist doctors has joined the drug pricing protests. This time, it's neuromuscular specialists, and they're targeting a forthcoming drug, Firdapse, ...

Brace yourselves: The drug pricing brouhaha isn’t dying down

Tracy Staton Drug prices were already a sore subject, but the pain grew this fall, when the now-former CEO of Turing Pharmaceuticals Martin Shkreli unapologetically jacked up the price ...

Baxalta and Momenta target AbbVie’s blockbuster with positive biosim data

Damian Garde Partners Baxalta and Momenta Pharmaceuticals, among the many contenders looking to challenge the world's top-selling drug, posted positive data for their take on AbbVie's ...

OrbiMed rings up $950M for its transatlantic biotech Fund VI

John Carroll OrbiMed has come through with a whopping $ 950 million biotech venture fund, committing anywhere from $ 10 million to a hefty $ 75 million to each of about 30 new companies. FierceBiotech ...

Wellcome invests $38M in another gene therapy startup, targeting hemophilia

Damian Garde The Wellcome Trust's investment arm is putting up £25 million ($ 38 million) to launch a new company developing a potential one-time treatment for hemophilia ...
Page 2 of 11812345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS